Biologic treatments for systemic rheumatic diseases

Oral Diseases

Volumn 14, Issue 3, 2008, Pages 206-216

  Shirota, Y ^a   Illei, G G ^a   Nikolov, N P ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

Autoimmunity; Biologic therapies; Monoclonal antibodies; Rheumatic diseases; Sj gren's syndrome

Indexed keywords

ABATACEPT; ADALIMUMAB; ATLIZUMAB; B CELL ACTIVATING FACTOR; B7 ANTIGEN; BASILIXIMAB; BELATACEPT; BELIMUMAB; CD20 ANTIGEN; CD22 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACLIZUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN M; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6 RECEPTOR; LYMPHOTOXIN; METHOTREXATE; MONOCLONAL ANTIBODY; MRA; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APLASTIC ANEMIA; AUTOIMMUNITY; BIOLOGICAL THERAPY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONNECTIVE TISSUE DISEASE; DEMYELINATING DISEASE; DISEASE ASSOCIATION; HUMAN; HYPERSENSITIVITY REACTION; IMMUNOGLOBULIN DEFICIENCY; INFECTION; INFLAMMATION; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MOUTH DISEASE; OPPORTUNISTIC INFECTION; PATHOGENESIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; RHEUMATIC DISEASE; RHEUMATOLOGY; SERUM SICKNESS; SJOEGREN SYNDROME; SYSTEMIC DISEASE; VASCULITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD22; ANTIRHEUMATIC AGENTS; B-CELL ACTIVATING FACTOR; HUMANS; IMMUNOCONJUGATES; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; INTERLEUKINS; LYMPHOCYTE ACTIVATION; RHEUMATIC DISEASES; SJOGREN'S SYNDROME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 40749120117     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2008.01440.x     Document Type: Review

References (130)

1. Anolik JH, Barnard J, Cappione A, et al (2004). Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 50:3580 3590.
2. Atkinson JC, Fox PC (1993). Sjogren's syndrome: oral and dental considerations. J Am Dent Assoc 124:74 76, 78 82, 84 86.
3. Azuma M, Aota K, Tamatani T, et al (2002). Suppression of tumor necrosis factor alpha-induced matrix metalloproteinase 9 production in human salivary gland acinar cells by cepharanthine occurs via down-regulation of nuclear factor kappaB: a possible therapeutic agent for preventing the destruction of the acinar structure in the salivary glands of Sjogren's syndrome patients. Arthritis Rheum 46:1585 1594.
4. Baecklund E, Ekbom A, Sparen P, et al (1998). Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 317:180 181.
5. Banner DW, D'Arcy A, Janes W, et al (1993). Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 73:431 445.
6. Bathon JM, Martin RW, Fleischmann RM, et al (2000). A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343:1586 1593.
7. Bave U, Nordmark G, Lovgren T, et al (2005). Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 52:1185 1195.
8. Bertolini DR, Nedwin GE, Bringman TS, et al (1986). Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 319:516 518.
9. Bluestone JA, St Clair EW, Turka LA, et al (2006). CTLA4Ig: bridging the basic immunology with clinical application. Immunity 24:233 238.
10. Bongartz T, Sutton AJ, Sweeting MJ, et al (2006). Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275 2285.
11. Boras VV, Cikes N, Lukac J, et al (2004). The significance of salivary and serum interleukin 6 and basic fibroblast growth factor levels in patients with Sjogren's syndrome. Coll Antropol 28 (Suppl. 2 305 309.
12. Borg FA, Isenberg DA (2007). Syndromes and complications of interferon therapy. Curr Opin Rheumatol 19:61 66.
13. Bretscher P, Cohn M (1970). A theory of self-nonself discrimination. Science 169:1042 1049.
14. Brookes SM, Cohen SB, Price EJ, et al (1996). T cell clones from a Sjogren's syndrome salivary gland biopsy produce high levels of IL-10. Clin Exp Immunol 103:268 272.
15. Check E (2007). Immunology: pimp my antibody. Nature 446:964 966.
16. Choy EH, Panayi GS (2001). Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907 916.
17. Cohen S, Hurd E, Cush J, et al (2002). Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46:614 624.
18. Cohen SB, Emery P, Greenwald MW, et al (2006). Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54:2793 2806.
19. Cummins MJ, Papas A, Kammer GM, et al (2003). Treatment of primary Sjogren's syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results. Arthritis Rheum 49:585 593.
20. Davidson A, Diamond B, Wofsy D, et al (2005). Block and tackle: CTLA4Ig takes on lupus. Lupus 14:197 203.
21. De Benedetti F, Massa M, Pignatti P, et al (1994). Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest 93:2114 2119.
22. Dinarello CA (1996). Biologic basis for interleukin-1 in disease. Blood 87:2095 2147.
23. Dorner T, Kaufmann J, Wegener WA, et al (2006). Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 8:R74.
24. Downie-Doyle S, Bayat N, Rischmueller M, et al (2006). Influence of CTLA4 haplotypes on susceptibility and some extraglandular manifestations in primary Sjogren's syndrome. Arthritis Rheum 54:2434 2440.
25. Edwards JC, Szczepanski L, Szechinski J, et al (2004). Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572 2581.
26. Elliott MJ, Feldmann M, Maini RN, et al (1993). Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 36:1681 1690.
27. Elliott MJ, Maini RN, Feldmann M, et al (1994). Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105 1110.
28. Elliott MJ, Maini RN, Feldmann M, et al (1995). TNF alpha blockade in rheumatoid arthritis: rationale, clinical outcomes and mechanisms of action. Int J Immunopharmacol 17:141 145.
29. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al (2006). The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54:1390 1400.
30. Ferraccioli GF, Salaffi F, De Vita S, et al (1996). Interferon alpha-2 (IFN alpha 2) increases lacrimal and salivary function in Sjogren's syndrome patients. Preliminary results of an open pilot trial versus OH-chloroquine. Clin Exp Rheumatol 14:367 371.
31. Fleishmann RM (2002). Safety of anakinra, a recombinant interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis and comparison to anti-TNF-alpha agents. Clin Exp Rheumatol 20 (5 Suppl. 27 S35 S41.
32. Furst DE, Schiff MH, Fleischmann RM, et al (2003). Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 30:2563 2571.
33. Furst DE, Breedveld FC, Kalden JR, et al (2007). Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 66 (Suppl. 3 iii2 iii22.
34. Genant HK, Peterfy CG, Westhovens R, et al (2007). Abatacept inhibits structural damage progression in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann Rheum Dis in press.
35. Genovese MC, Bathon JM, Martin RW, et al (2002). Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 46:1443 1450.
36. Genovese MC, Cohen S, Moreland L, et al (2004). Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 50:1412 1419.
37. Genovese MC, Becker JC, Schiff M, et al (2005). Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353:1114 1123.
38. Goldbach-Mansky R, Dailey NJ, Canna SW, et al (2006). Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 355:581 592.
39. Gorman JD, Sack KE, Davis JC, Jr., et al (2002). Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 346:1349 1356.
40. Gottenberg JE, Busson M, Cohen-Solal J, et al (2005a). Correlation of serum B lymphocyte stimulator and beta2 microglobulin with autoantibody secretion and systemic involvement in primary Sjogren's syndrome. Ann Rheum Dis 64:1050 1055.
41. Gottenberg JE, Guillevin L, Lambotte O, et al (2005b). Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 64:913 920.
42. Gridley G, McLaughlin JK, Ekbom A, et al (1993). Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 85:307 311.
43. Grondal G, Gunnarsson I, Ronnelid J, et al (2000). Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 18:565 570.
44. Groom J, Kalled SL, Cutler AH, et al (2002). Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 109:59 68.
45. Helbling D, Breitbach TH, Krause M, et al (2002). Disseminated cytomegalovirus infection in Crohn's disease following anti-tumour necrosis factor therapy. Eur J Gastroenterol Hepatol 14:1393 1395.
46. Hirano T, Matsuda T, Turner M, et al (1988). Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol 18:1797 1801.
47. Horai R, Saijo S, Tanioka H, et al (2000). Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 191:313 320.
48. Isomaki HA, Hakulinen T, Joutsenlahti U, et al (1978). Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis 31:691 696.
49. Kalliolias GD, Georgiou PE, Antonopoulos IA, et al (2007). Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial. Ann Rheum Dis 66:842 843.
50. Kamath BM, Mamula P, Baldassano RN, et al (2002). Listeria meningitis after treatment with infliximab. J Pediatr Gastroenterol Nutr 34:410 412.
51. Kassan SS, Thomas TL, Moutsopoulos HM, et al (1978). Increased risk of lymphoma in sicca syndrome. Ann Intern Med 89:888 892.
52. Keffer J, Probert L, Cazlaris H, et al (1991). Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 10:4025 4031.
53. Kelm S, Pelz A, Schauer R, et al (1994). Sialoadhesin, myelin-associated glycoprotein and CD22 define a new family of sialic acid-dependent adhesion molecules of the immunoglobulin superfamily. Curr Biol 4:965 972.
54. Keystone EC, Kavanaugh AF, Sharp JT, et al (2004a). Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50:1400 1411.
55. Keystone EC, Schiff MH, Kremer JM, et al (2004b). Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 50:353 363.
56. Khoury SJ, Akalin E, Chandraker A, et al (1995). CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J Immunol 155:4521 4524.
57. Khurshudian AV (2003). A pilot study to test the efficacy of oral administration of interferon-alpha lozenges to patients with Sjogren's syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 95:38 44.
58. Kohler G, Milstein C (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495 497.
59. Kremer JM, Westhovens R, Moreland LW, et al (2003). Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 349:1907 1915.
60. Kremer JM, Genant HK, Leon M, et al (2006). Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 144:865 876.
61. Lavie F, Miceli-Richard C, Quillard J, et al (2004). Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjogren's syndrome. J Pathol 202:496 502.
62. Lazarus MN, Robinson D, Mak V, et al (2006). Incidence of cancer in a cohort of patients with primary Sjogren's syndrome. Rheumatology (Oxford) 45:1012 1015.
63. Leandro MJ, Edwards JC, Edwards JC, et al (2002). Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 61:883 888.
64. Leandro MJ, Cambridge G, Cambridge G, et al (2005). B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 44:1542 1545.
65. Lee JH, Slifman NR, Gershon SK, et al (2002). Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 46:2565 2570.
66. Lenschow DJ, Ho SC, Sattar H, et al (1995). Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med 181:1145 1155.
67. Linker-Israeli M, Deans RJ, Wallace DJ, et al (1991). Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol 147:117 123.
68. Lipsky PE, van der Heijde DM, St Clair EW, et al (2000). Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343:1594 1602.
69. Looney RJ, Anolik JH, Campbell D, et al (2004). B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I-/-II dose-escalation trial of rituximab. Arthritis Rheum 50:2580 2589.
70. Lovell DJ, Giannini EH, Reiff A, et al (2000). Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 342:763 769.
71. Madhok R, Crilly A, Watson J, et al (1993). Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis 52:232 234.
72. Maini R, St Clair EW, Breedveld F, et al (1999). Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354:1932 1939.
73. Maini RN, Breedveld FC, Kalden JR, et al (2004). Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 50:1051 1065.
74. Maini RN, Taylor PC, Szechinski J, et al (2006). Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54:2817 2829.
75. Mariette X, Roux S, Zhang J, et al (2003). The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 62:168 171.
76. Mariette X, Ravaud P, Steinfeld S, et al (2004). Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS). Arthritis Rheum 50:1270 1276.
77. Matteson EL, Hickey AR, Maguire L, et al (1991). Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD Registry. Rheumatoid Arthritis Azathioprine Registry Steering Committee. J Rheumatol 18:809 814.
78. Mease PJ, Goffe BS, Metz J, et al (2000). Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356:385 390.
79. Mohan N, Edwards ET, Cupps TR, et al (2001). Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 44:2862 2869.
80. Mohan AK, Cote TR, Block JA, et al (2004). Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 39:295 299.
81. Moreland LW, Baumgartner SW, Schiff MH, et al (1997). Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337:141 147.
82. Moreland LW, Schiff MH, Baumgartner SW, et al (1999). Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 130:478 486.
83. Naka T, Nishimoto N, Kishimoto T, et al (2002). The paradigm of IL-6: from basic science to medicine. Arthritis Res 4 (Suppl. 3 S233 S242.
84. Nakelchik M, Mangino JE (2002). Reactivation of histoplasmosis after treatment with infliximab. Am J Med 112:78.
85. Nishimoto N (2006). Interleukin-6 in rheumatoid arthritis. Curr Opin Rheumatol 18:277 281.
86. Nishimoto N, Yoshizaki K, Miyasaka N, et al (2004). Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 50:1761 1769.
87. Nishimoto N, Hashimoto J, Miyasaka N, et al (2007). Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66:1162 1167.
88. O'Keefe TL, Williams GT, Batista FD, et al (1999). Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies. J Exp Med 189:1307 1313.
89. Otipoby KL, Andersson KB, Draves KE, et al (1996). CD22 regulates thymus-independent responses and the lifespan of B cells. Nature 384:634 637.
90. Perrier S, Coussediere C, Dubost JJ, et al (1998). IL-1 receptor antagonist (IL-1RA) gene polymorphism in Sjogren's syndrome and rheumatoid arthritis. Clin Immunol Immunopathol 87:309 313.
91. Peterson E, Robertson AD, Emlen W, et al (1996). Serum and urinary interleukin-6 in systemic lupus erythematosus. Lupus 5:571 575.
92. Pijpe J, van Imhoff GW, Spijkervet FK, et al (2005). Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum 52:2740 2750.
93. Pincus T, Callahan LF (1986). Taking mortality in rheumatoid arthritis seriously - predictive markers, socioeconomic status and comorbidity. J Rheumatol 13:841 845.
94. Pincus T, Callahan LF, Sale WG, et al (1984). Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 27:864 872.
95. Present DH, Rutgeerts P, Targan S, et al (1999). Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340:1398 1405.
96. Reff ME, Carner K, Chambers KS, et al (1994). Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435 445.
97. Ricart E, Panaccione R, Loftus EV, et al (2001). Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 96:722 729.
98. Richette P, Dieude P, Damiano J, et al (2004). Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis. J Rheumatol 31:2079 2081.
99. Saklatvala J (1986). Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 322:547 549.
100. Sankar V, Brennan MT, Kok MR, et al (2004). Etanercept in Sjogren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum 50:2240 2245.
101. Seror R, Sordet C, Guillevin L, et al (2007). Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. Ann Rheum Dis 66:351 357.
102. Shiozawa S, Morimoto I, Tanaka Y, et al (1993). A preliminary study on the interferon-alpha treatment for xerostomia of Sjogren's syndrome. Br J Rheumatol 32:52 54.
103. Shiozawa S, Tanaka Y, Shiozawa K, et al (1998). Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with Sjogren's syndrome. J Interferon Cytokine Res 18:255 262.
104. Ship JA, Fox PC, Michalek JE, et al (1999). Treatment of primary Sjogren's syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: a phase II clinical trial. IFN Protocol Study Group. J Interferon Cytokine Res 19:943 951.
105. Smith KG, Jones RB, Burns SM, et al (2006). Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 54:2970 2982.
106. St Clair EW, van der Heijde DM, Smolen JS, et al (2004). Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50:3432 3443.
107. Steinfeld SD, Tant L, Burmester GR, et al (2006). Epratuzumab (humanized anti-CD22 antibody) in primary Sjogren's syndrome: an open-label phase I/II study. Arthritis Res Ther 8:R129.
108. Tackey E, Lipsky PE, EIllei GG, et al (2004). Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus 13:339 343.
109. Targan SR, Hanauer SB, van Deventer SJ, et al (1997). A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337:1029 1035.
110. Tedder TF, Tuscano J, Sato S, et al (1997). CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Annu Rev Immunol 15:481 504.
111. Thatayatikom A, White AJ (2006). Rituximab: a promising therapy in systemic lupus erythematosus. Autoimmun Rev 5:18 24.
112. Theander E, Henriksson G, Ljungberg O, et al (2006). Lymphoma and other malignancies in primary Sjogren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 65:796 803.
113. Thomas E, Hay EM, Hajeer A, et al (1998). Sjogren's syndrome: a community-based study of prevalence and impact. Br J Rheumatol 37:1069 1076.
114. Tornwall J, Lane TE, Fox RI, et al (1999). T cell attractant chemokine expression initiates lacrimal gland destruction in nonobese diabetic mice. Lab Invest 79:1719 1726.
115. Tyndall A, Walker UA, Cope A, et al (2007). Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005. Arthritis Res Ther 9:301.
116. Van Deventer SJ (1997). Tumour necrosis factor and Crohn's disease. Gut 40:443 448.
117. van Dullemen HM, van Deventer SJ, Hommes DW, et al (1995). Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109:129 135.
118. Vincenti F, Luggen M (2007). T cell costimulation: a rational target in the therapeutic armamentarium for autoimmune diseases and transplantation. Annu Rev Med 58:347 358.
119. Warris A, Bjorneklett A, Gaustad P, et al (2001). Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 344:1099 1100.
120. Weinblatt ME, Kremer JM, Bankhurst AD, et al (1999). A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253 259.
121. Weinblatt ME, Keystone EC, Furst DE, et al (2003). Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48:35 45.
122. Weinblatt M, Schiff M, Goldman A, et al (2007). Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis 66:228 234.
123. Weisman MH, Moreland LW, Furst DE, et al (2003). Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther 25:1700 1721.
124. Williams RO, Feldmann M, Maini RN, et al (1992). Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 89:9784 9788.
125. Winterfield LS, Menter A (2004). Infliximab. Dermatol Ther 17:409 426.
126. Woo P, Wilkinson N, Prieur AM, et al (2005). Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther 7:R1281 R1288.
127. Yildirim MA, Goh KI, Cusick ME, et al (2007). Drug-target network. Nat Biotechnol 25:1119 1126.
128. Yokota S, Miyamae T, Imagawa T, et al (2005). Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 52:818 825.
129. Zhang J, Roschke V, Baker KP, et al (2001). Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 166:6 10.
130. Zhu Z, Stevenson D, Schechter JE, et al (2003). Tumor necrosis factor inhibitor gene expression suppresses lacrimal gland immunopathology in a rabbit model of autoimmune dacryoadenitis. Cornea 22:343 351.